NISCI (Nogo-A Inhibition in acute Spinal Cord Injury)
is a multicenter, multinational, placebo controlled phase-II study for the safety and preliminary efficacy of intrathecal anti-Nogo-A [NG101] in patients with acute cervical spinal cord injury.
The purpose of the NISCI trial is to test if an antibody therapy can improve motor function and quality of life of tetraplegic patients. A previous trial showed this treatment is safe and well accepted. This current trial has been approved by the National Ethics Committee and Ministry of Health for all participating trial sites.
Find NISCI under Clinical Trials.gov